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In countries around the world and in research
across nearly every field of technology and inno!
vation, patents provide a means to harvest the
value of inventions and control their distribu!
tion and use.  A patent provides its owner the
right to exclude others from making, using and
selling the subject matter of the patent [1].
These important rights enable the patent holder
to control, during the term of the patent, the
development and commercial distribution of its
technology.  
The Importance of Patenting
For academic and research institutions, patent
protection can be a particularly effective vehicle
for ensuring that technology developed in the
laboratory is not only the subject of scholarly
publication, but also becomes embodied in a
product or service that reaches the marketplace
in a manner that allows the public to benefit
from scientific advances. Patent protection
additionally provides a vehicle for the individu!
als and institutions whose innovative contribu!
tions and financial resources are used to be com!
pensated for their academic and economic
investment.  All too frequently, important sci!
ence developed at universities and other
research institutions is commercialized by com!
panies in the private sector without any rewards
– monetary or otherwise – to the university or
institution, or to its scientists.  
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Abstract: Patent protection can be a tremendously useful tool for transferring technology from the research
laboratory to the commercial marketplace.  However, many misconceptions exist – especially in the aca!
demic world – about how to effectively and efficiently make use of patent protection.  By overcoming some
of the common myths and making informed decisions about when and where to pursue patent protection,
research institutions and their scientists can benefit significantly.  Patent protection is available across a
wide range of technologies, but the availability of patent protection alone may not be a sufficient basis upon
which to determine whether to pursue patent protection.  This is because the mere availability of patent pro!
tection does not necessarily equate to commercial viability of the underlying technology.  Thus, a further
analysis of the technology's commercial potential can be quite important in making informed decisions
about the patent process.  
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Patents are a principal intellectual property
mechanism that researchers and their institu!
tions can utilize to protect scientific advances
and secure some financial return when those
advances are embodied in commercial products
and services.  This often occurs through the
establishment of a business relationship
between the academic institution and/or scien!
tist and a company in the private sector.
Depending upon local law and the preferences
of the institution or its researchers, as well as
the stage in development and other aspects of
the technology at issue, such business relation!
ships can take any number of forms.  For
instance, these relationships might involve the
license or sale of the patents and/or patent
applications relating to the technology, but can
also involve the establishment of new compa!
nies with venture capital financing or more
expansive collaborative research arrangements.
Alternatively, if, without an existing business
relationship, a company commercializes a prod!
uct or service that infringes on the rights of a
patent holder, whether that patent holder is a
large academic institution or an individual sci!
entist, the institution or scientist may seek
enforcement of its intellectual property rights
through legal proceedings.  If successful, such
legal proceedings should result in the patent
holder being awarded monetary damages based
on the illicit commercialization of its patented
product or service.  Whether a business rela!
tionship is formed to commercialize a product or
a patent holder pursues legal action to enforce
its intellectual property rights, the goal is the
same: securing a financial return for the com!
mercialization of technology developed at the
institution.  Absent patent protection, this can
be a difficult or entirely impossible goal for an
academic institution or its researchers to
achieve.
In fact, the existence of patent protection
for technology developed at an academic insti!
tution can be a critical issue for companies in
the private sector insofar as the company's
interest in a business opportunity with the insti!
tution is concerned.  If an institution is con!
ducting research in a particular field and dili!
gently pursuing patent protection, then there
are likely to be legitimate intellectual property
assets for companies to purchase or license.
Once a company acquires an interest in that
intellectual property, it may enjoy a significant
advantage in the market with respect to its com!
petitors.  The added leverage of licensed patents
can be a tremendous advantage for companies
that would otherwise be left to simply compete
in the marketplace.  Indeed, strong patent pro!
tection can offer the company a period of mar!
ket exclusivity.  The possibility of effective mar!
ket exclusivity can be critical for the company's
business objectives.  This is important for aca!
demic and research institutions to appreciate, if
attracting licensing revenue or research funding
from the private sector is of interest.  
Furthermore, it is often the case that tech!
nology developed at academic or research insti!
tutions for which patent protection is not
sought is not commercialized.  Without the pos!
sibility of market exclusivity through patent
protection, companies may not have any inter!
est in devoting the necessary time and resources
to commercializing the unpatented product.
This is frequently the case in the fields of
biotechnology and the life sciences, where the
existence of patent protection can mean the dif!
ference between a company taking an interest in
commercializing a technology or ignoring it
entirely.  Thus, if an institution's goal is to see
the technology it develops reach the public,
then patent protection may be a critical issue to
consider.
In sum, patents provide a mechanism for
academic institutions and their scientists to
reap the financial rewards of scientific successes,
while also providing an incentive for companies
to partner with institutions and scientists in
bringing their technology to market.
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Determining Whether Patent Protection 
is Appropriate
Patent protection can be an important compo!
nent of collaborations between academic and
research institutions and companies in the pri!
vate sector.  However, patent protection is not
available in every instance, and, even in those
instances where it is available, pursuing patent
protection is not always advisable.  It is thus
important to consider whether patent protec!
tion is appropriate before investing the
resources required to procure it.  This is espe!
cially true at academic and research institu!
tions, where limited resources may be available
for this sometimes costly process.  
Before seeking patent protection, it is
worthwhile to first consider if an innovation is
patentable.  This is a preliminary question that
many institutions and scientists routinely
investigate before initiating the patenting
process.  Oftentimes, however, the preliminary
inquiry ends at that stage, and the decision on
whether to pursue patent protection is based
merely on whether that protection seems to be
available.  Yet, if patent protection seems to be
available, there is a second and quite important
issue to consider.  That is whether patent pro!
tection would be valuable.  Indeed, there are
many instances where an invention meets all of
the legal and technical requirements for
patentability, and a patent can therefore be
obtained.  But the mere fact that an invention is
patentable does not mean that the technology is
inherently valuable.  More specifically, it does
not mean that business opportunities will exist
or that the technology will be commercialized.
If business opportunities do not exist and the
technology will not be commercialized, then
there is not likely to be much value for an aca!
demic institution in having secured patent pro!
tection.  Indeed, even the most exciting aca!
demic advances may not have any commercial
relevance.
It is therefore important, especially for aca!
demic institutions, to consider whether there is
significant commercial potential for a technolo!
gy before seeking patent protection, or at a min!
imum, to consider this issue early in the patent!
ing process.  It is the commercial potential of a
technology, and not its academic interest alone,
that makes patent protection worthwhile.  
Assessing Patentability
In most countries, an invention is patentable if
is meets several requirements: it must be novel
[2], it must involve an inventive step (or is
"non!obvious") [3], and it must have industrial
applicability (or "utility") [4].  Particularly in
the fields of biotechnology and the life sciences,
one must additionally consider if the invention
can be adequately described and defined so as to
support patent claims.  It is often the case that
research in these fields provides important
insight into the physiology of a human or animal
system, such as by discovering a relevant gene
or molecular target.  However, while such dis!
coveries may have tremendous importance for
understanding health and disease, it does not
necessarily translate into a patentable pharma!
ceutical or diagnostic technique without sub!
stantial further research.  
An invention is typically deemed to be
novel if it was not known prior to its discovery
(and the filing of a patent application) by the
inventor.  Inventive step is generally based on a
determination that the invention would not
have been obvious to a skilled artisan in that sci!
entific field.  These issues – novelty and inven!
tive step – are at the center of the patenting
process, and result in the greatest amount of dis!
cussion and disagreement between patent appli!
cants and patent offices around the world.
Industrial applicability, however, is typically
not a significant obstacle to obtaining a patent,
so long as a patent application is directed solely
to subject matter for which patent protection is
26
Special Issue
SCIENCE  AND  INNOVATION. N 4, 2005
available in a particular jurisdiction.  For exam!
ple, laws of nature are generally not patentable,
and in some locations, methods of medical or
surgical treatment are not patentable [5].
Similarly, patent protection is available only to
limited degrees in many countries for computer
software inventions.
Patentability is typically assessed by con!
ducting a review of the prior art to determine if
the invention meets the criteria for patentabili!
ty (i.e., novelty, inventive step) in jurisdictions
of interest.  Any concerns regarding
unpatentable subject matter or research that
cannot support patent claims are also assessed.
Evaluating Commercial Potential
A patent is a useful mechanism to protect and
harvest the value of an invention to the extent
that value actually exists or is likely to exist in
the foreseeable future.  Some inventions have
far greater commercial value than others.  This
often appears contrary to the importance of an
invention from a purely academic perspective.
Consider, for example, two new pharmaceuti!
cals; one that is effective in treating a common!
place yet serious medical condition prevalent in
adults around the world, and another that is
useful in the treatment of a disease that has no
discernable symptoms or means of diagnosis and
affects few people.  In this very basic example, it
should be clear why a patent for the former
could have significant commercial value (based
on the size of the market and the severity of the
condition) while the opposite is likely to be true
for the latter (based on the limited market size
and the lack of ability to readily diagnose the
condition).  This is a very simple example, but
underscores the importance of considering the
commercial potential of an invention before
investing resources in securing patent protec!
tion.  Indeed, the question of a technology's
potential commercial value is typically much
more complex.  One must consider an array of
factors, and these factors will vary across differ!
ent technologies.  Some, but not all of these fac!
tors include the following.
Size and Nature of the Market
The size and nature of the market for a technol!
ogy are important factors to consider.  A prod!
uct that is expected to be purchased by many
people could be more valuable than a product
that only few people find useful.  However,
despite the fact that the size of a market may be
very small, a product that sells at a high price
may still have significant commercial value.
Another consideration is whether one or more
comparable products already exist in the mar!
ket, or whether the invention relates to truly
new technology that can itself define a new mar!
ket.  
Relevant Business Transactions
In most cases, an academic institution or indi!
vidual scientist will not commercialize a prod!
uct on its own.  Instead, a business relationship
will be formed with a company in the private
sector that is better positioned to commercialize
the technology.  These relationships typically
involve either a license or sale of the patents or
other forms of intellectual property protection
that relate to the technology.  Thus, gaining an
understanding of the types of terms that can be
expected in such a transaction can be quite
informative.  The financial terms may include
licensing fees, royalties for product sales, mile!
stone payments, equity in a company, or a host
of other forms of consideration.  It may be help!
ful to know, for example, that the vast majority
of the licenses for a particular type of technolo!
gy involve a small, one!time licensing fee, rather
than more robust royalty provisions based on
product sales.
Depending upon the area of technology and
the particular industry in which it finds applica!
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tion, certain relevant information can be
obtained through a variety of sources.  There are
a number of services to which one can subscribe
that compile this type of information on a regu!
lar basis.  Additionally, in some countries, such
as the United States, publicly traded companies
are required to make certain information avail!
able to the public.  In certain instances, this can
include the details of the companies' licensing
transactions and other business arrangements
with academic and research institutions.  A
number of other sources can also be examined
for information in this respect.
Legal Obstacles to Commercialization
The commercial value of a new technology can
be significantly impacted by the scope of related
patent protection that has been obtained by
others in the field.  For example, it is not uncom!
mon for medical research to identify a new use
for an existing pharmaceutical for which one or
more patents are held by a particular company.
Depending upon the nature of that company's
patent protection, it may be impossible to com!
mercialize the novel indication without the con!
sent of that company.  To proceed otherwise may
result in an infringement of the company's
patents.  Even if a tremendous market exists for
the novel indication and it seems to be over!
whelmingly valuable upon examination of simi!
lar business transactions, the technology may
not be licensable to anyone other than that one
company.  This can be a challenging situation
for an academic or research institution.  If the
company is interested in a business transaction
(e.g., because it extends the possible patent cov!
erage for the product), then that may generate a
positive result for the institution.  If, however,
the company is not interested in a business
transaction, the institution may have difficulty
identifying other business partners.
Public Perception
Particularly in the life sciences and biotechnol!
ogy, one must consider the public perception of
a technology to understand whether it is likely
to be successful in the market.  By way of exam!
ple, advances in gene therapeutics and stem cell
research have created exciting new possibilities
for scientific and medical breakthroughs.
However, the public outcry in various parts of
the world about the routine implementation of
these technologies should be considered in
assessing the breadth of companies in the pri!
vate sector that may be interested in attempting
to commercialize these technologies and the
likelihood that a commercial product will reach
the market.
Where to Pursue Patent Protection
Once a decision is made to pursue patent pro!
tection, one must consider where to do so.  One
common misconception is that one can obtain a
single "international patent."  This is not true.
Certain international treaties provide a harmo!
nized system for filing patent applications and
pursuing patent protection [6], but, ultimately,
patents are awarded on a country!by!country
basis. Thus, patent applicants must decide
where to pursue patent protection.
While there are a range of issues to consid!
er in making this determination, three general
themes apply across a wide range of technolo!
gies typically developed at academic and
research institutions.  First, one might consider
where the technology will actually be mar!
ketable and have cognizable commercial value.
Countries with a limited or nonexistent market
for a particular technology are generally not
worthwhile jurisdictions in which to pursue
patent protection.  Second, one might weigh the
possible market value of a technology in a par!
ticular country against the cost of obtaining
patent protection.  In some countries, pursuing
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patent protection can be quite expensive, and
the potential return on that investment may not
be sufficient to justify seeking patent protec!
tion.  Third, one must consider whether patent
protection is generally enforceable in a particu!
lar country of interest. Some countries have
effective systems in place that enable patent
holders to enforce their patents against
infringers, while enforcement in other countries
can be challenging. Before incurring the
expense of patent protection, one must consider
whether it will be an effective tool to protect the
patent holder's intellectual property rights in
that country.
Publishing versus Patenting
One of the most prevalent myths associated
with pursuing patent protection is the idea that
one must choose between either patenting or
publishing the results of one's research.  It is
simply not true that one must choose one or the
other.  Quite to the contrary, it is entirely com!
monplace for scientists at academic and
research institutions to publish the results of
their research in scholarly journals and to pres!
ent the same at conferences, while also (usually
simultaneously) pursuing patent protection.
The misconception among scientists that these
are mutually exclusive is a significant obstacle
for academic and research institutions that wish
to protect the intellectual property developed
by their researchers.  
There is an extremely important caveat,
however.  While one need not choose between
patenting and publishing, these activities are
interrelated and must be carefully coordinated
to avoid the loss of patent rights.  Most coun!
tries require that a patent application be filed
prior to any public disclosure of the invention.
This requirement is referred to as "absolute nov!
elty."  Most countries define a "public disclo!
sure" as a publication, oral presentation, public
display or public use.  It would thus not be pos!
sible to obtain a valid patent in an "absolute
novelty" country if the invention is publicly dis!
closed prior to filing a patent application.
Absolute novelty countries include, for exam!
ple, countries that are party to the European
Patent Convention [7], Japan, and Ukraine.
This is slightly different in the United States,
where inventors have a one!year grace period in
which to file a patent application following pub!
lic disclosure or the offer for sale or actual sale of
a product or service that embodies their inven!
tion [8].
The ability to freely and expeditiously pub!
lish the results of one's research is critical to
many in academia.  It is therefore equally criti!
cal that academic and research institutions have
available to them resources to speedily file
patent applications where necessary to protect
inventions without hampering scientists' free!
dom to publish or disclose the results of their
research.  Internal systems can be established at
academic institutions to account for this con!
cern, and efficient patent counsel can typically
prepare and file a patent application without
requiring significant delay in the publication or
disclosure of an invention.  In fact, in the United
States, a mechanism is available that enables a
patent applicant to file a "provisional" patent
application, which does not require all of the
formalities of a standard patent application [9].
This mechanism is often used when a patent
application must be filed quickly.
Timeline for Patenting
The Patent Cooperation Treaty ("PCT") is the
principal mechanism that makes it possible to
seek patent protection for an invention simulta!
neously in multiple countries.  An international
patent application may generally be filed with a
national patent office of a country that is party
to the PCT (or with the International Bureau of
the World Intellectual Property Organization
in Geneva).  Where appropriate, the application
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may alternatively be filed with the European
Patent Office ("EPO"), the African Regional
Industrial Property Organization ("ARIPO")
or the Eurasian Patent Office ("EAPO").  This
application may include a claim of priority to a
domestic patent application filed no more than
one year prior to the filing of the international
application.  
Once the international patent application is
filed, the applicant must initiate national phase
prosecution in each jurisdiction of interest
before the expiration of the particular national
phase filing deadline. Depending upon the
country or region and the manner in which the
applicant conducted the international phase of
patent prosecution, this deadline can be any!
where from 20 to 42 months from the applica!
tion's filing or priority date; although, in most
countries, the deadline is either 30 or 31
months.  
After national phase prosecution is initiat!
ed, the speed with which patent offices around
the world conduct patent prosecution varies
dramatically.  On average, however, a patent
applicant can typically expect a patent to issue
within about 3–4 years of initiating national
phase prosecution. In most jurisdictions, a
patent has a term of 20 years, measured from its
earliest priority date.
1. See, e.g., 35 United States Code § 271.
2. See, e.g., 35 United States Code § 102; European
Patent Convention Articles 52(1) and 54.
3. See, e.g., 35 United States Code § 103; European
Patent Convention Articles 52(1) and 56.
4. See, e.g., 35 United States Code § 101; European
Patent Convention Articles 52(1) and 57.
5. See, e.g., European Patent Convention Article 52(4). 
6. See, e.g., the Paris Convention for the Protection of
Industrial Property (1883), the Patent Cooperation
Treaty (1970), the Patent Law Treaty (2000), the
Budapest Treaty on the International Recognition of
the Deposit of Microorganisms for the Purposes of
Patent Procedure (1977), and the Strasbourg
Agreement Concerning the International Patent
Classification (1971). 
7. Article 54(2) of the European Patent Convention
(EPC) creates an "absolute novelty" requirement.
EPC countries presently include Austria, Belgium,
Bulgaria, Switzerland, Cyprus, Czech Republic,
Germany, Denmark, Estonia, Spain, Finland, France,
United Kingdom, Hellenic Republic, Hungary,
Ireland, Iceland, Italy, Liechtenstein, Lithuania,
Luxembourg, Latvia, Monaco, Netherlands, Poland,
Portugal, Romania, Sweden, Slovenia, Slovakia and
Turkey. 
8. See 35 United States Code §§ 102(a), 102(b)
9. See 35 United States Code § 111.
